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Self-assembly and stabilization of hybrid cowpea chlorotic mottle 
virus particles under nearly physiological conditions 
Suzanne B. P. E. Timmermans+,[a]  Daan F. M. Vervoort+,[a] Lise Schoonen[a], Roeland J. M. Nolte[b] and 
Jan C. M. van Hest*[a] 
Abstract: Capsids of the cowpea chlorotic mottle virus (CCMV) hold 
great promise for use as nanocarriers in vivo. A major drawback, 
however, is the lack of stability of the empty wild-type virus particles 
under physiological conditions. Here, we report on the assembly 
behavior and stability under nearly-physiological conditions of 
protein-based block copolymers composed of the CCMV capsid 
protein and two hydrophobic elastin-like polypeptides. UV-vis 
spectrometric studies, dynamic light scattering analysis, and 
transmission electron microscopy measurements demonstrate that 
both hybrid variants form stable capsids at pH 7.5, physiological 
NaCl concentration and 37°C. The more hydrophobic variant also 
remains stable in a cell culture medium. These engineered hybrid 
CCMV capsid particles can therefore be regarded as suitable 
candidates for in vivo applications. 
Introduction 
Hollow particles with sizes in the nanometer range (nanocages) 
have found widespread application in the medical field. For 
instance, the encapsulation of pharmaceutical drugs inside 
nanocages has tremendously increased the control over drug 
delivery on the molecular level.[1,2] By modifying the exterior of 
the particles, targeting towards a desired tissue can be achieved, 
reducing the side effects of the drug. At the same time, the 
nanocage enhances the stability of the drug and increases its 
half-life in vivo by shielding it from interfering external influences.  
The success of these types of designs is illustrated by liposomal 
drug delivery systems that are now on the market or in clinical 
trials.[3] The same can be said for polymeric nanoformulations, of 
which many are now being evaluated clinically, showing great 
promise for future applications.[4] Potential in vivo applications of 
nanocarriers are not limited to the drug delivery field. There are 
also opportunities in the field of artificial organelles, where 
nanocarriers can be used to replace dysfunctional enzymes in 
diseased cells or to extend the endogenous biosynthetical 
pathways of the cell.[5] 
Although liposomal and polymeric nanocages evidently show 
great potential as in vivo nanocarriers, they have some 
disadvantageous properties. For instance, the lipid- and 
polymer-based subunits intrinsically form assemblies with a 
relatively large size distribution, which can only be controlled to 
a certain extent. In contrast, protein-based nanocages are very 
well-defined in both size and shape, as they are formed from a 
specific number of proteins. In addition, these nanoparticles are 
biocompatible, biodegradable, and robust.[2,6]  It is therefore not 
surprising that recent developments enabling (future) in vivo use 
have been made with both natural protein cages, such as 
ferritin[7–9], bacterial encapsulins[10,11] and the bacteriophage 
P22[12–14], as well as with designed protein cages[15–17]. In 
particular, virus-like particles (VLPs), i.e. viruses devoid of their 
endogenous genetic material, are promising vehicles for 
nanocarrier purposes, as their natural role is to safely transport 
the viral genome to the right place in the host organism.[18,19] In 
vivo studies have already indicated the great potential of these 
systems as nanocarriers for biological purposes.[20–24] 
Of particular interest is the cowpea chlorotic mottle virus (CCMV) 
capsid. This VLP distinguishes itself from other viral nanocages 
through its reversible assembly behavior. At neutral pH, capsid 
protein dimers exist in solution, which spontaneously assemble 
into 28 nm sized capsids with a triangulation number T = 3 upon 
lowering the pH to 5.0.[25,26] This process is completely reversible, 
and, remarkably, can take place without the viral RNA being 
present. This allows facile loading of a cargo into the capsids, 
which is essential for the application of CCMV capsids as 
nanocarriers.[27] Cargo encapsulation can be achieved in two 
ways: (i) in a statistical fashion, i.e. the cargo is added to the 
capsid protein dimers and the pH of the solution is lowered to 
5.0 to induce capsid formation and simultaneous cargo 
encapsulation;[28,29] or (ii) through the attachment of a cargo to 
the capsid protein N-termini. In this way the cargo ends up on 
the inside of the capsid after assembly.[30,31] A major 
disadvantage of the wild-type CCMV VLP is that it is not stable 
under physiological conditions: at neutral pH the capsids 
disassemble again into capsid protein dimers. Nevertheless, 
successful in vitro and in vivo studies with CCMV have been 
reported.[20,32,33] These studies, however, involved stabilized 
capsids, i.e. capsids encapsulating the viral RNA or a negatively 
charged synthetic polymer mimicking the nucleic acid. Although 
these polymers offer the required stabilization at physiological 
conditions, their presence makes the encapsulation of an 
additional cargo challenging. Therefore, we are interested in 
tuning the stability of the capsid proteins such, that no additional 
compound, e.g. the negatively-charged polymer, is required to 
keep the capsids stable at physiological conditions. 
Previously, a variant of the CCMV capsid protein was developed 
in our laboratory, which involved the substitution of the cationic 
nucleic acid-binding domain at the N-terminus by a short elastin-
like polypeptide (ELP).[34] ELPs are stimulus-responsive peptides, 
consisting of repeating VPGXG pentapeptides (where the guest 
residue X can be any amino acid except proline). These 
peptides can be reversibly switched from a water-soluble state 
to an insoluble, hydrophobic state, upon changes in the 
environmental conditions, such as the temperature or salt 
concentration.[35] In addition, ELP phase transitions are 
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dependent on the hydrophobicity of the guest residues, number 
of repeats and ELP concentration. The introduction of this 
stimulus-responsive peptide to the CCMV capsid proteins 
resulted in an expansion of their assembly properties: upon an 
increase of the temperature or salt concentration, spontaneous 
assembly into smaller T = 1 particles of roughly 18 nm was 
achieved at pH 7.5.[34] Although 2 M NaCl was still needed to 
achieve assembly, this assembly could at least be realized at a 
physiologically relevant pH. Further studies were aimed at 
introducing more hydrophobic guest residues in the ELP domain, 
with the objective to lower the amount of NaCl needed to 
assemble the capsids at physiological concentrations.[36] It was 
shown that changing only one or two out of the nine guest 
residues in the ELP fragment was enough to observe a 
significant decrease in the so-called ‘transition salt 
concentration’. In particular, the two most hydrophobic variants 
caught our attention, as these remarkably assembled at 150 mM 
NaCl, which is close to the physiological salt concentration, 
indicating the potential of these ELP modified CCMV capsids as 
nanocarriers for in vivo studies. 
Here, we present studies aimed at further investigating the 
potential of these two ELP-CCMV variants as carrier vehicles at 
physiological conditions. To this end, we thoroughly studied the 
assembly behavior of these capsid proteins, taking into account 
the possibility to encapsulate a cargo in the capsids. We aimed 
at developing a working protocol that involves disassembly of 
the capsids for potential cargo encapsulation, followed by 
reassembly to stable particles, such that experiments at 
physiological conditions can be performed. Particular attention 
will therefore be given to the aspects of capsid stability and the 
reversibility of the assembly process for cargo loading purposes. 
Results and Discussion 
Design of hydrophobic ELP-CCMV variants 
In order to create ELP-CCMV variants with higher stability at 
lower salt concentrations, hydrophobic residues were introduced 
in the ELP-domain of the ELP-CCMV capsid protein. Hereto, the 
native ELP-CCMV construct containing a H6 tag (H6-ELP-
CCMV(∆N26)) was used as the initial variant. This ELP 
sequence, VPGVG-VPGLG-VPGVG-VPGLG-VPGVG-VPGLG-
VPGGG-VPGVG-VPGLG, contains as guest residues (the fourth 
amino acid of each pentapeptide repeat) four times a valine, four 
times a leucine, and once a glycine. This species can also be 
described by the general notation ELP[V4L4G1-9], where the ratio 
of the guest residues is mentioned, followed by the number of 
pentapeptide repeats. 
The two most promising hydrophobic ELP-CCMV variants, VY1-
VY8 ELP-CCMV (ELP[Y2V2L4G1-9]) and VW1-VW8 ELP-CCMV 
(ELP[W2V2L4G1-9]) were developed by introducing  valine to 
tyrosine and  valine to tryptophan mutations, respectively, at the 
guest-residue of the first and eighth ELP pentapeptide. The 
introduction of the ELP fragment allows us to induce both pH-
induced (T = 3 particles) and ELP-induced assembly (T = 1 
particles), in which the ELP assembly behavior is dependent on 
salt and capsid protein concentration, pH, temperature, and 
time.[35] 
 
 
 
Figure 2: Overview of the assembly states of VY1-VY8 ELP-CCMV in
various buffers after incubation for 1 hour at the indicated temperature. The
remaining soluble protein fraction was determined by UV-vis spectroscopy
and is highlighted with colours (red = 0%-24%, orange = 25%-49%, yellow =
50%-74% and green = 75%-100%). The particle size was measured by DLS
and is shown in the panels as pH-induced particles (pH 5.0, left), ELP-
induced particles and dimers (pH 7.5, middle), dimers and aggregates (pH
7.5, right). The assembly state at physiological conditions is indicated with a
box. The corresponding DLS intensity distributions and UV-vis absorbance
spectra can be found in the SI (Figures S9-S14). 
Figure 1: Overview of the assembly states of native ELP-CCMV in various
buffers after incubation for 1 hour at the indicated temperature. The 
remaining soluble protein fraction (in either dimer or particle form) was 
determined by UV-vis spectroscopy and is highlighted with colours (red =
0%-24% and green = 75%-100%). The particle size was measured by DLS
and is shown in the panels as pH-induced particles (pH 5.0, left), ELP-
induced particles (pH 7.5 middle), dimers and aggregates (pH 7.5, right).
The corresponding DLS intensity distributions and UV-vis absorbance 
spectra can be found in the SI (Figures S1-S6). 
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Assembly behavior of the ELP-CCMV variants 
In order to investigate the assembly behavior and stability of 
these ELP-CCMV variants, the pH-induced, hollow T = 3 
particles were either diluted in a pH 5.0 buffer or spin-filtrated to 
a pH 7.5 buffer with NaCl concentrations ranging from 150 to 
2500 mM and a final protein concentration of 20 µM. The 
stability of the ELP-CCMV variants in the pH 7.5 buffer was of 
interest for in vivo applications, while the experiments in the pH 
5.0 buffer allowed a comparison of the stability of the ELP-
induced particles with that of the pH-induced particles. The 
assembly behavior and stability was followed over time by 
dynamic light scattering (DLS) and UV-vis spectroscopy. When 
protein aggregation occurred, the samples became considerably 
turbid. The soluble protein concentration was measured at 
several time points by determining the absorbance at 280 nm 
after removal of the precipitated protein.  
In a first series of experiments the assembly behavior and 
stability of the native ELP-CCMV were determined in several 
buffers (Figure 1). Interestingly, this native ELP-CCMV showed 
surprisingly high stability up to 50°C in pH 5.0 buffer (T = 3 
particles by pH-induced assembly), however over an extended 
incubation period in these conditions a large fraction of the 
protein aggregated. In pH 7.5 buffer containing 2.5 M NaCl (T = 
1 particles by ELP-induced assembly) the protein also 
demonstrated high stability, however at more physiological 
relevant salt concentrations (500 mM NaCl) capsid assembly did 
not occur, as we reported previously, indicating the need for 
more hydrophobic variants.[36]  
Figure 3: Optimization of capsid assembly at pH 7.5. A) Schematic representation of all steps of the different methods. Method 1 comprises overnight 
dialysis of a 100 µM VY1-VY8 ELP-CCMV solution to pH 7.5 buffer supplemented with 100 mM NaCl to render coat protein dimers, followed by spin-filtration 
to pH 7.5 buffer with 150 mM NaCl, dilution to 20 µM VY1-VY8 ELP-CCMV and subsequent incubation at 37°C. In method 2 the temperature is increased 
with 1°C per min. after dilution of the protein solution and before incubation at 37°C. In method 3 the solution of VY1-VY8 ELP-CCMV coat protein dimers is 
spin-filtered to pH 7.5 buffer supplemented with 500 mM NaCl, subsequently diluted to 100 µM protein, after which the temperature is increased to a) 21°C or 
b) 30°C. The protein solution is then incubated at these temperatures for 30 minutes to allow capsid self-assembly. Finally, the solution is diluted to 20 µM 
VY1-VY8 ELP-CCMV and 150 mM NaCl and incubated at 37°C. In method 4 the temperature is slowly increased with 1°C per min. after dilution of the 
solution to 20 µM protein and 150 mM NaCl, and before incubation at 37°C. B) Number distributions after 1 h and 2 h of incubation at 37°C and at a final 
protein concentration of 20 µM, as determined by DLS. The corresponding intensity distributions are given in the SI (Figure S15).  
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Next, the assembly behavior of both hydrophobic variants was 
determined (see SI Figure 7). DLS experiments showed that the 
capsids of these variants remained assembled in pH 5.0 buffer. 
Interestingly, in pH 7.5 buffer containing 500 mM NaCl the 
capsids did not completely disassemble, indicating the higher 
stability of these hydrophobic variants compared to the native 
ELP-CCMV. Since ELP-CCMV assembly behavior and stability 
are dependent on many variables, i.e. salt, capsid protein 
concentration, pH, temperature, and time,[35] a more extensive 
dialysis was performed overnight at 4°C to achieve full 
disassembly of these more hydrophobic variants. Although the 
native and VY1-VY8 ELP-CCMV showed complete disassembly 
towards dimeric capsid proteins after this extended protocol, the 
VW1-VW8 ELP-CCMV capsid proteins remained fully 
assembled. Additional experiments showed that disassembly of 
the VW1-VW8 ELP-CCMV variant even was not achieved after 
further reducing the NaCl concentration and protein 
concentration to 0 µM and 5 µM, respectively (see SI Figure 8).   
Since the hydrophobic variant, VY1-VY8 ELP-CCMV, displayed 
reversible assembly behavior, we decided to continue the study 
of the assembly behavior and stability of this ELP-capsid protein 
variant in the same way as was done for the native ELP-CCMV, 
with the exception that an extensive dialysis overnight at 4°C 
was performed in order to achieve complete disassembly 
(Figure 2). Compared to the native ELP-CCMV, the VY1-VY8 
ELP-CCMV variant showed comparable stability up to 50°C in 
pH 5.0 buffer. Interestingly, the stability in pH 7.5 buffer 
containing 500 mM NaCl was considerably increased, resulting 
in fairly stable T = 1 particles up to 37°C. However, self-
assembly into stable capsids did not occur in a buffer with a 
nearly-physiological NaCl concentration (150 mM).  
 
Optimization of capsid assembly in nearly-physiological 
buffer 
As the VY1-VY8 ELP-CCMV coat protein was unstable in pH 7.5 
buffer containing 150 mM NaCl, manifested by severe protein 
aggregation, we attempted to improve the protein stability in this 
buffer. Our initial data suggested (Figure 2, Figure 3Error! 
Reference source not found.) that aggregation of the VY1-VY8 
ELP-CCMV coat protein occurred quicker than capsid assembly 
at a 20 µM concentration in pH 7.5 buffer with 150 mM NaCl. 
Therefore, we opted to find a procedure that reduced 
aggregation and at the same time accelerated capsid formation. 
At physiological pH, the assembly of VY1-VY8 ELP-CCMV 
capsids is driven by the N-terminal ELP domain[34] and is thus a 
kinetic process dependent on e.g. protein and NaCl 
concentration, and temperature[35], as opposed to 
thermodynamically driven self-assembly known for other peptide 
domains.[37]  Accordingly, we initially adapted the existing 
protocol by adding a gradual temperature increase to 37°C 
before incubating the protein solution at this temperature 
(Method 2 in Figure 3 A). The rationale behind this approach 
was to allow the capsid proteins to slowly undergo temperature-
induced changes at temperatures that are suitable for capsid 
assembly, but do not induce aggregation. Although this 
approach indeed reduced the degree of aggregation, capsid 
assembly was not improved sufficiently. Therefore, we focused 
on the other factors that can influence ELP self-assembly and 
increased the initial protein and NaCl concentrations to 100 µM 
and 500 mM, respectively, in order to further promote capsid 
formation. In addition, we allowed the VY1-VY8 ELP-CCMV coat 
Figure 4: Capsid assembly state and protein stability of 20 µM VY1-VY8
ELP-CCMV in pH 7.5 buffer with 150 mM NaCl  after initial capsid self-
assembly at 100 µM VY1-VY8 ELP-CCMV, 500 µM NaCl and 21°C (a, b)
and in DMEM after initial capsid self-assembly at 200 µM VY1-VY8 ELP-
CCMV and 25°C in DMEM (c, d). Number distributions (a, c) were
determined by DLS after 1 h, 4 h, 7 h, and 24 h of incubation at the indicated
temperatures. The corresponding intensity distributions can be found in SI
Figure S19 and S30. The remaining soluble protein percentage (b, d) was
determined by UV-vis spectroscopy and is plotted against the incubation
time. The corresponding spectra can be found in SI Figure S20 and S31. 
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protein to self-assemble at 21°C or 30°C, temperatures that did 
not induce protein aggregation, before dilution to 20 µM VY1- 
VY8 ELP-CCMV and 150 mM NaCl and subsequent incubation 
at 37°C (Method 3 in Figure 3 A). This approach resulted in the 
 
 
 
formation of capsids that remained assembled at 37°C for at 
least 2 hours, while protein aggregation was minimized. A 
further change in the procedure, i.e. by introducing a gradual 
temperature increase after capsid formation, right before 
incubation at 37°C, did not improve capsid self-assembly or 
stability further (Method 4 in Figure 3 A), indicating that VY1-
VY8 ELP-CCMV capsids are less sensitive to temperature 
changes than coat protein dimers or intermediate assemblies. 
 
Stability of VY1-VY8 ELP-CCMV capsids in nearly-
physiological buffer 
After having established that we can stabilize VY1-VY8 ELP-
CCMV capsids under nearly-physiological conditions, we were 
interested in determining the fate of these capsids during 
prolonged incubation. Hereto, we first assembled capsids via 
method 3a (Figure 3 A) and then incubated these particles at 
temperatures ranging from 4°C to 50°C for up to 24 hours. 
Capsid assembly state and protein stability were evaluated with 
the help of DLS and UV-vis spectroscopy, respectively. In order 
to get a better understanding of what factors are important in 
determining the protein stability and assembly state, we 
compared the fate of VY1-VY8 ELP-CCMV capsids with the 
nanocages formed by a less hydrophobic variant, i.e. native 
ELP-CCMV. We discovered that the capsids formed by VY1-
VY8 ELP-CCMV coat proteins remained assembled at 
temperatures above 21°C in the buffer that mimics physiological 
conditions, while at 4°C no capsids  
could be observed by DLS (Figure 4 A). In addition, the protein 
demonstrated remarkable stability at 30°C for at least 24 h. More  
importantly, even at 37°C it was quite stable in the considered 
time period, with the protein concentration gradually decreasing 
over time (Figure 4 B). Transmission electron microscopy (TEM) 
analysis (Table 1, Figure S34) confirmed that capsids were 
present at 37°C during the complete 24 hour incubation period. 
Interestingly, the native ELP-CCMV coat protein, lacking the two 
hydrophobic tyrosine residues in its ELP domain, did not remain 
assembled in the same buffer conditions (see SI Figure S16, 
S17, and S18), indicating the importance of capsid stabilization 
by ELP assembly. More importantly, while the protein 
sequences of the VY1-VY8 ELP-CCMV and native ELP-CCMV 
coat proteins only differ by the two valine to tyrosine 
substitutions in the ELP domain, the native ELP-CCMV protein 
is much less stable at 37°C and 50°C than the VY1-VY8 ELP-
CCMV variant (SI). This suggests that the formation of capsids 
increases the stability of the ELP-CCMV coat proteins even at 
elevated temperatures. 
 
Assembly and stability of VY1-VY8 ELP-CCMV capsids in 
cell culture medium 
After having established that capsids of the VY1-VY8 ELP-
CCMV variant were fairly stable in a buffer that mimicked 
physiological conditions, it was evaluated whether capsids would 
also remain intact in a cell culture medium (Dulbecco's Modified 
Eagle Medium, DMEM), which resembles in vivo conditions 
even closer. Hereto, it was first attempted to assemble VY1-VY8 
ELP-CCMV capsids in DMEM by incubating a 100 µM protein 
solution in this buffer for 30 minutes at 21°C, in a procedure very 
similar to the optimized capsid assembly protocol described 
above. However, no capsid assembly was observed in this way 
(see Figure S23). Therefore, the assembly protocol was further 
optimized by increasing the VY1-VY8 ELP-CCMV concentration 
to 200 µM, the assembly temperature to 25°C, and the induction 
time to 1 hour (see Figure S25 and S26). These conditions 
provided a balance between fast capsid formation, which was 
accelerated by the increased coat protein concentration and 
elevated temperature (see Figure S23 and S25), and reduction 
of temperature-induced protein aggregation (see Figure S24 and 
S26). In addition, the prolonged incubation time ensured that 
capsids remained stable upon dilution to 20 µM (Figure S25). 
We employed the optimized protocol for the evaluation of the 
stability of VY1-VY8 ELP-CCMV in DMEM at temperatures 
ranging from 4°C to 50°C. DLS analysis was performed in order 
to determine the assembly state, while the protein concentration 
in solution was monitored by UV-vis spectroscopy. Initially UV-
vis measurements in DMEM were troublesome, as light-induced 
degradation of components in the DMEM solution interfered with 
our measurements, as also observed previously in the 
literature.[38] We could minimize the occurrence of these 
artefacts by protecting the DMEM and protein solutions therein 
from light irradiation during all steps of the procedure (Figure 
S27). 
When we compare the results in DMEM with those in the nearly-
physiological buffer we see similar trends, although the overall 
stability of the hydrophobic VY1-VY8 ELP-CCMV variant was 
reduced (Figure 4). The VY1-VY8 ELP-CCMV variant only 
remained assembled into capsids at temperatures from 30°C 
and above, while the coat protein itself was very stable at 4°C 
and 21°C (Figure 4 C, D). Most of the protein was lost within 1 
hour at 37°C and 50°C. TEM analysis confirmed these findings 
(Table 1, Figure S35). It is most likely that some of the 
components in the DMEM solution have a destabilizing effect on 
ELP-CCMV capsid assembly, since we ruled out the possibility 
that the NaCl concentration is the limiting factor (Figure S28 and 
S29) and the ionic strengths of the nearly-physiological buffers 
and DMEM formulation are comparable. Nonetheless, the VY1-
VY8 ELP-CCMV is promising for in vivo studies, especially since 
the stability can be further improved in the future by e.g. cross-
linking of the capsid proteins. 
 
Table 1. Particle sizes as determined by TEM analysis. The ELP-CCMV 
variants were incubated in either pH 7.5 buffer with 150 mM NaCl (called 
Buffer) or DMEM at 37 °C for the indicated time period prior to TEM sample 
preparation. 
ELP-CCMV 
variant 
 Buffer, 1 h Buffer, 24 
h 
DMEM, 1 h DMEM, 24 h 
Native 
ELP-CCMV 
No particles No particles Not 
determined 
Not 
determined 
VY1-VY8 
ELP-CCMV 
22.8 ± 2.4 
nm 
23.1 ± 2.1 
nm 
21.7 ± 1.8 
nm[a] 
No particles[a] 
VW1-VW8 
ELP-CCMV 
26.3 ± 2.0 
nm 
25.5 ± 2.0 
nm 
24.0 ± 2.2 
nm 
No particles 
[a] Incubated at 30°C, as no particles were found to be present at 37°C 
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Stability of VW1-VW8 ELP-CCMV capsids under nearly 
physiological conditions 
Since the VY1-VY8 ELP-CCMV variant was found to have 
promising stability under nearly-physiological conditions, we 
decided to also evaluate the more hydrophobic and perhaps 
more stable VW1-VW8 ELP-CCMV variant. The fact that we 
could not disassemble its capsids, even at reduced protein and 
NaCl concentrations or in the absence of the stabilizing MgCl2,  
(see SI Figure S8 A, B), was a first indication of improved 
stability. This was further supported by DLS data that suggested 
that the coat proteins already assembled into capsids during 
bacterial expression (see SI Figure S8 C, D). Therefore, we 
investigated the fate of VW1-VW8 ELP-CCMV capsids during 
prolonged incubation at nearly-physiological conditions. When 
we incubated capsids of this hydrophobic variant in the nearly-
physiological buffer in the same way as for the VY1-VY8 ELP-
CCMV variant, we found that the more hydrophobic VW1-VW8 
ELP-CCMV coat protein remained assembled into capsids even 
at 4°C in the same buffer conditions (Figure 5 A, B). More 
importantly, the VW1-VW8 ELP-CCMV protein is much more 
stable at 37°C and 50°C than the VY1-VY8 ELP-CCMV variant. 
This suggests that the increased hydrophobicity of the ELP 
domain further enhances capsid stability at elevated 
temperatures. When we incubated capsids formed by the VW1-
VW8 ELP-CCMV variant in DMEM, we again found the capsids 
of this variant to be more stable than the ones formed by the 
less hydrophobic VY1-VY8 ELP-CCMV variant. The VW1-VW8 
ELP-CCMV protein remained assembled into capsids at all 
temperatures that were tested and was very stable at 
temperatures up to 30°C (Figure 5 C, D). However, at 50°C it 
quickly degraded, while at 37°C it degraded gradually over a 
time course of 7 hours, which allows sufficient time for in vivo 
uptake studies. Thus, with its increased stability compared to 
VY1-VY8 ELP-CCMV, the VW1-VW8 variant is very suitable for 
in vivo applications where especially a stable protein cage is 
required.  
Combined, our findings in nearly-physiological buffer and DMEM 
demonstrate the importance of stabilization of the ELP-CCMV 
capsids in order to increase the resistance of the protein 
nanocage to elevated temperatures. Between 21°C and 30°C 
the coat protein is sufficiently stable by itself, but above this 
temperature range capsid assembly is required to prevent 
uncontrolled protein aggregation. Furthermore, we demonstrated 
that by making subtle adjustments in the assembly conditions 
we could induce striking changes in capsid stability. In general 
the introduction of hydrophobic residues in the ELP domain 
greatly increases capsid stability and this stability may be further 
enhanced in the future by making modifications in the capsid 
exterior or encapsulating stabilizing cargoes. In addition, it is 
likely that a crowded environment such as the cell interior will 
further stabilize ELP-CCMV capsids by physically hampering 
disassembly. 
Conclusions 
We have extensively studied the assembly behavior and stability 
of two ELP-CCMV variants, which are promising for in vivo 
studies. As we demonstrated, the VY1-VY8 ELP-CCMV protein 
can be reversibly assembled and disassembled, which is 
advantageous for future cargo encapsulation prior to in vivo 
studies. After optimization of the assembly protocol, capsids of 
this variant were stable in pH 7.5, 150 mM NaCl buffer at 37°C 
for 7 hours and in DMEM for around 1 h, which is approximately 
the time scale for cellular uptake. Capsids assembled from the 
VW1-VW8 ELP-CCMV protein were even more stable, as they 
remained assembled for at least 24 h in pH 7.5, 150 mM NaCl 
buffer at 37 °C and for 4-7 hours in DMEM. So far, we did not 
succeed in fully disassembling capsids formed by this more 
hydrophobic variant. This may be problematic for cargo loading, 
although a solution could be to employ in vivo cargo loading 
during capsid protein expression, which is common practice for 
several other VLPs.[39,40] Remaining challenges for future 
research are the further improvement of the stability of the VY1-
VY8 ELP-CCMV variant and to find other ways for encapsulating 
cargo inside capsids formed by the VW1-VW8 ELP-CCMV 
variant. 
Experimental Section 
Buffers. pH 5.0 capsid buffer: 50 mM NaOAc, 500 mM NaCl, 10 mM 
MgCl2, 1 mM EDTA, pH 5.0. pH 7.5 62.5 mM NaCl buffer: 50 mM 
Tris·HCl, 62.5 mM NaCl, 10 mM MgCl2, 1 mM EDTA, pH 7.5. pH 7.5 100 
mM NaCl buffer: 50 mM Tris·HCl, 100 mM NaCl, 10 mM MgCl2, 1 mM 
Figure 5: Capsid assembly state and protein stability of 20 µM VW1-VW8
ELP-CCMV in pH 7.5 buffer with 150 mM NaCl  after initial capsid self-
assembly at 100 µM VW1-VW8 ELP-CCMV, 500 µM NaCl and 21°C (a, b)
and in DMEM after initial capsid self-assembly at 200 µM VW1-VW8 ELP-
CCMV and 25°C in DMEM (c, d).Number distributions (a, c) were determined
by DLS after 1 h, 4 h, 7 h, and 24 h of incubation at the indicated
temperatures. The corresponding intensity distributions can be found in SI
Figure S21 and S32. The remaining soluble protein percentage (b, d) was
determined by UV-vis spectroscopy and is plotted against the incubation
time. The corresponding spectra can be found in SI Figure S22 and S33. 
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EDTA, pH 7.5. pH 7.5 150 mM NaCl buffer: 50 mM Tris·HCl, 150 mM 
NaCl, 10 mM MgCl2, 1 mM EDTA, pH 7.5. pH 7.5 500 mM NaCl buffer: 
50 mM Tris·HCl, 500 mM NaCl, 10 mM MgCl2, 1 mM EDTA, pH 7.5. pH 
7.5 2500 mM NaCl buffer: 50 mM Tris·HCl, 2500 mM NaCl, 10 mM 
MgCl2, 1 mM EDTA, pH 7.5. 
General expression and purification protocol. The pET-15b-H6-ELP-
CCMV(∆N26), pET-15b-H6-VY1-VY8-ELP-CCMV(∆N26) and pET-15b-
H6-VW1-VW8-ELP-CCMV(∆N26) vectors encoding for the three ELP-
CCMV variants used in this paper have previously been constructed[34,36].  
E.coli BLR(DE3)pLysS containing any of these vectors were cultured 
overnight at 37°C in 50 mL LB medium containing ampicillin (100 mg/L) 
and chloramphenicol (50 mg/L).  The overnight culture was used to 
inoculate 2xTY medium (1 L), containing ampicillin (100 mg/L). Protein 
expression was done by inducing exponentially growing bacteria (OD600 
between 0.4 – 0.6) with 1 mM IPTG at 30°C for 5-6 hours. Bacteria were 
lysed by ultrasonic disruption.  Purification was done by immobilized 
metal affinity chromatography. Proteins were dialyzed against pH 5.0 
capsid buffer (2 times 30-60 minutes), followed by overnight dialysis 
using a 12-14 kDa tubing) for stable storage at 4°C. The purity and 
characteristics of the protein were verified and determined by SDS-PAGE, 
SEC, Q-TOF, DLS and TEM. 
General protocol for assembly and stability assays: For a typical 
assembly and stability assay, an ELP-CCMV variant (100 µM) was 
dialyzed overnight to pH 7.5, 100 mM NaCl buffer (12-14 kDa MWCO, 2 
x 30 min + o.n., 4°C). Subsequently the protein was spin-filtered to either 
pH 7.5 buffer 500mM NaCl (buffer experiments) or DMEM (DMEM 
experiments) (10 kDa MWCO, 3 x 10 min, 4°C). For buffer experiments, 
a pre-incubation solution of 100 µM ELP-CCMV variant was prepared, 
heated to 21°C with 1°C/min and incubated for 30 minutes at this 
temperature to allow capsid assembly. For DMEM experiments, the pre-
incubation solution contained 200 µM of the ELP-CCMV variant and was 
heated to 25°C with 1°C/min before incubation at the final temperature 
for 1 hour to induce self-assembly into capsids. The protein solutions 
were then diluted with pH 7.5, 62.5 mM NaCl buffer (for buffer 
experiments) or DMEM (for DMEM experiments) to a final concentration 
of 20 µM ELP-CCMV variant and incubated at temperatures ranging from 
4°C to 50°C for up to 24 h. After 0, 1, 4, 7, and 24h samples were taken 
for DLS and UV-vis analysis to assess assembly state and stability of the 
ELP-CCMV variant respectively. All samples were centrifuged twice prior 
to analysis.  
For further detailed procedures see the Supporting Information. 
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